Description
The ipamorelin and CJC 1295 blend combines two research peptides that target different parts of growth hormone signaling. CJC-1295 without DAC is a modified GHRH-related peptide used to examine GHRH receptor activity, while ipamorelin is a five-amino-acid growth hormone secretagogue associated with ghrelin receptor activation. Together, they support laboratory research into pituitary response, growth hormone release, receptor activity, and broader GH-axis regulation.
CJC ipamorelin side effects vary by component, concentration, and experimental conditions, so observed responses differ across study models. CJC ipamorelin dosage depends on assay design, concentration requirements, and protocol parameters, thereby supporting controlled evaluation of GH-axis signaling and peptide-specific response patterns.
Features
- Composition: CJC-1295 without DAC and Ipamorelin research peptide blend
- CJC-1295 No DAC Type: Modified GHRH-related peptide
- Ipamorelin Structure: Five-amino-acid peptide
- Ipamorelin Class: Growth hormone secretagogue
Disclaimer: Supplied strictly for laboratory research. Not intended for human or veterinary administration, consumption, diagnosis, treatment, or therapeutic use.
Reviews
There are no reviews yet.